Circular RNA profiling identifies circ5078 as a BMPR2-derived regulator of endothelial translation. VandenBroek MM, Sharp MC, Thompson P, Fagbola E, Quilty D, Mewburn JD, Theilmann AL, Archer SL, Renwick N, Ormiston ML. bioRxiv. 2023 Sep 18.
IFN-β activates cytotoxic function of human natural killer cells toward IL-27 and poly(I:C) stimulated PC3 and DU145 cells. Kourko O, Hawke LG, Ormiston ML, Gee K. Cell Immunol. 2023 Apr 8;387:104718.
Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics. Coyle KM, Hawke LG, Ormiston ML. Cancers. 2023 Mar 13;15(6):1743.
Targeting BMPR-II in pulmonary arterial hypertension: a case of Hercules versus the Hydra? VandenBroek MM, Skebo SI, Ormiston ML. Expert Opin Ther Targets. 2022 Dec;26(12):1027-1030.
Oh NO! Loss of PHD2 leads to "radical" changes in the lung vasculature. Ormiston ML, Jankov RP, Stewart DJ. Eur Respir J. 2022 Dec 22;60(6):2201776.
Impaired Interleukin-15 Signaling via BMPR2 Loss Drives Natural Killer Cell Deficiency and Pulmonary Hypertension. Hilton LR, Rätsep MT, VandenBroek MM, Jafri S, Laverty KJ, Mitchell M, Theilmann AL, Smart JA, Hawke LG, Moore SD, Renaud SJ, Soares MJ, Morrell NW, Ormiston ML. Hypertension. 2022 Nov;79(11):2493-2504
Evolving Concepts in Endothelial Pathobiology of Pulmonary Arterial Hypertension. Cober ND, VandenBroek MM, Ormiston ML, Stewart DJ. Hypertension. 2022 Aug;79(8):1580-1590
Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer. Harry JA, Ormiston ML. Front Oncol. 2021 Dec 3;11:772305.
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling. Theilmann AL, Hawke LG, Hilton LR, Whitford MKM, Cole DV, Mackeil JL, Dunham-Snary KJ, Mewburn J, James PD, Maurice DH, Archer SL, Ormiston ML. Arterioscler Thromb Vasc Biol. 2020 Nov;40(11):2605-2618.
The Production of Pro-angiogenic VEGF-A Isoforms by Hypoxic Human NK Cells Is Independent of Their TGF-β-Mediated Conversion to an ILC1-Like Phenotype. Hawke LG, Whitford MKM, Ormiston ML. Front Immunol. 2020 Aug 25;11:1903.
TGF-β and IL-15 Synergize through MAPK Pathways to Drive the Conversion of Human NK Cells to an Innate Lymphoid Cell 1-like Phenotype. Hawke LG, Mitchell BZ, Ormiston ML. J Immunol. 2020 Jun 15;204(12):3171-3181.
Phosphodiesterase 3B (PDE3B) antagonizes the anti-angiogenic actions of PKA in human and murine endothelial cells. MacKeil JL, Brzezinska P, Burke-Kleinman J, Theilmann AL, Nicol CJB, Ormiston ML, Maurice DH. Cell Signal. 2019 Oct;62:109342.
Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future? Theilmann AL, Ormiston ML. Eur Respir J. 2019 Jun 5;53(6).
Legumain in Pulmonary Arterial Hypertension. Hilton LR, Ormiston ML. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):536-537.
The Janus Faces of Bone Morphogenetic Protein 9 in Pulmonary Arterial Hypertension. Ormiston ML, Godoy RS, Chaudhary KR, Stewart DJ. Circ Res. 2019 Mar 15;124(6):822-824.
Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction. Karmouty-Quintana H, Guignabert C, Kwapiszewska G, Ormiston ML. Front Physiol. 2018 Dec 10;9:1777.
Growth/differentiation factor 15 causes TGFβ-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertension. Garfield B, Crosby A, Shao D, Yang P, Paul R, Sawiak S, Ormiston ML, Moore S, Parfitt L, Harries C, Morrell NW, Polkey M, Wort SJ, Kemp P. Thorax. 2019 Feb;74(2):164-176.
Spontaneous pulmonary hypertension in genetic mouse models of natural killer cell deficiency. Ratsep MT, Moore SD, Jafri S, Mitchell M, Brady HJ, Mandelboim O, Southwood M, Morrell NW, Colucci F, Ormiston ML. Am J Physiol Lung Cell Mol Physiol. 2018 Dec 1;315(6):L977-L990.
A Potential Role for Exosomal TCTP Export in Vascular Remodeling in Pulmonary Arterial Hypertension. Ferrer E, Dunmore BJ, Hassan D, Ormiston ML, Moore S, Deighton J, Long L, Yang XD, Stewart DJ, Morrell NW. Am J Respir Cell Mol Biol. 2018 Oct;59(4):467-478.
Pulmonary arterial hypertension: pathogenesis and clinical management. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. BMJ. 2018 Mar 14;360:j5492.
Epigenetic Dysregulation of the Drp1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications. Chen KH, Dasgupta A, Lin J, Potus F, Bonnet S, Iremonger J, Fu J, Mewburn J, Wu D, Dunham-Snary K, Theilmann AL, Jing ZC, Hindmarch C, Ormiston ML, Lawrie A, Archer SL. Circulation. 2018 Feb 5. [Epub ahead of print]
Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities. Jafri S, Ormiston ML. Am J Physiol Regul Integr Comp Physiol. 2017 Dec 1;313(6):R693-R705.
Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2. Caruso P, Dunmore BJ, Schlosser K, Schoors S, Dos Santos C, Perez-Iratxeta C, Lavoie JR, Zhang H, Long L, Flockton AR, Frid MG, Upton PD, D'Alessandro A, Hadinnapola C, Kiskin FN, Taha M, Hurst LA, Ormiston ML, Hata A, Stenmark KR, Carmeliet P, Stewart DJ, Morrell NW. Circulation. 2017 Dec 19;136(25):2451-2467.
A sex-specific reconstitution bias in the competitive CD45.1/CD45.2 congenic bone marrow transplant model. Jafri S, Moore SD, Morrell NW, Ormiston ML. Sci Rep. 2017 Jun 14;7(1):3495.
Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients. Selvam SN, Casey LJ, Bowman ML, Hawke LG, Longmore AJ, Mewburn J, Ormiston ML, Archer SL, Maurice DH, James P. Blood Coagul Fibrinolysis. 2017 Oct;28(7):521-533.
MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. Hong Z, Chen KH, DasGupta A, Potus F, Dunham-Snary K, Bonnet S, Tian L, Fu J, Breuils-Bonnet S, Provencher S, Wu D, Mewburn J, Ormiston ML, Archer SL. Am J Respir Crit Care Med. 2017 Feb 15;195(4):515-529.
Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood. Ormiston ML, Toshner MR, Kiskin FN, Huang CJ, Groves E, Morrell NW, Rana AA. JoVE. 2015 Dec 23;(106):e53384.
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension. Ormiston ML, Upton PD, Li W, Morrell NW. Glob Cardiol Sci Pract. 2015 Nov 17;2015(4):47.
Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2+/- Mice with Schistosomiasis. Crosby A, Soon E, Jones FM, Southwood MR, Haghighat L, Toshner MR, Raine T, Horan I, Yang P, Moore S, Ferrer E, Wright P, Ormiston ML, White RJ, Haight DA, Dunne DW, Morrell NW. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1355-65.
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Long L, Ormiston ML (joint first author), Yang X, Southwood M, Gräf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, Moore SD, Drake KM, Aldred MA, Yu PB, Upton PD, Morrell NW. Nat Med. 2015 Jul;21(7):777-85.
Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Lavoie JR, Ormiston ML (joint first author), Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, Caruso P, Southwood M, Foster WS, Morrell NW, Stewart DJ. Circulation. 2014 May 27;129(21):2125-35.
Transcript analysis reveals a specific HOX signature associated with positional identity of human endothelial cells. Toshner M, Dunmore BJ, McKinney EF, Southwood M, Caruso P, Upton PD, Waters JP, Ormiston ML, Skepper JN, Nash G, Rana AA, Morrell NW. PLoS One. 2014 Mar 20;9(3):e91334.
Assessment of a pulmonary origin for blood outgrowth endothelial cells by examination of identical twins harboring a BMPR2 mutation. Ormiston ML, Southgate L, Treacy C, Pepke-Zaba J, Trembath RC, Machado RD, Morrell NW. Am J Respir Crit Care Med. 2013 Jul 15;188(2):258-60.
A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension. Ormiston ML, Deng Y, Rundle N, Bendjelloul F, Tsoporis JN, Parker TG, Stewart DJ, Courtman DW. Am J Pathol. 2013 May;182(5):1541-51.
A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells. Geti I, Ormiston ML (joint first author), Rouhani F, Toshner M, Movassagh M, Nichols J, Mansfield W, Southwood M, Bradley A, Rana AA, Vallier L, Morrell NW. Stem Cells Transl Med. 2012 Dec;1(12):855-65.
Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Ormiston ML, Chang C, Long LL, Soon E, Jones D, Machado R, Treacy C, Toshner MR, Campbell K, Riding A, Southwood M, Pepke-Zaba J, Exley A, Trembath RC, Colucci F, Wills M, Trowsdale J, Morrell NW. Circulation. 2012 Aug 28;126(9):1099-109.
Late outgrowth endothelial progenitor cells engineered for improved survival and maintenance of function in transplant-related injury. Zhao J, Bolton EM, Ormiston ML, Bradley JA, Morrell NW, Lever AM. Transpl Int. 2012 Feb;25(2):229-41.
Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Ormiston ML, Deng Y, Stewart DJ, Courtman DW. Am J Respir Cell Mol Biol. 2010 Nov;43(5):546-54.
The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension. Ormiston ML, Slaughter GR, Deng Y, Stewart DJ, Courtman DW. Am J Physiol Lung Cell Mol Physiol. 2010 Feb;298(2):L148-57.
Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells. Karoubi G, Ormiston ML, Stewart DJ, Courtman DW. Biomaterials. 2009 Oct;30(29):5445-55.
MRI characterization of agarose gel micro-droplets at acute time-points within the rabbit lumbar muscle. Foltz WD, Ormiston ML, Stewart DJ, Courtman DW, Dick AJ. Biomaterials. 2008 Apr;29(12):1844-52.
Chapter 7: Pathobiology of pulmonary hypertension. in Pulmonary Circulation: Diseases and their Treatment, 4th Edition. Ormiston ML and Morrell NW. Edited by A Peacock, R. Naeije and L.J. Rubin. Taylor and Francis Group Ltd, Oxford, UK. April 11, 2016. pp. 79-95.
Chapter 9: Targeting BMPR-II deficiency for the treatment of pulmonary arterial hypertension in Recent Advances in Cardiology, Volume 17. Ormiston ML and Morrell NW. Edited by Derek Rowlands and Bernard Clarke. JP Medical Ltd, London, UK. September 9, 2015. pp 115-130.
Chapter 16.7: Stem Cell Therapy in Pulmonary Circulation, 3rd Edition. Ormiston ML, Courtman DW, Stewart DJ. Edited by A Peacock, R. Naeije and L.J. Rubin. Hodder Arnold, London, UK. Published May 27, 2011.
Cellular Substrate for Nuclear Reprogramming. Morrell NW, Ormiston ML, Rana AA, Vallier L. Filed: March 30, 2011. Published: October 4, 2012, World Intellectual Property Organization.
EU Patent #: EP 2 691 514 B1, Granted: September 6, 2017
US Patent #: US 9 963 681 B2, Granted: May 8, 2018
Copyright © 2023 Ormiston Lab - All Rights Reserved.